Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

類似資料

• Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience
  著者:: Yingyi He, 等
  出版事項: (2023-03-01)
• Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death
  著者:: Avedis Torossian, 等
  出版事項: (2019-07-01)
• Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
  著者:: Joelle C. Boulos, 等
  出版事項: (2021-11-01)
• ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
  著者:: Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, 等
  出版事項: (2024-09-01)
• ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
  著者:: Jikui Guan, 等
  出版事項: (2024-01-01)